复星医药(02196.HK)自研新药XH-S004在内地治疗COPD启动Ib期临床试验

阿斯达克财经
17 Jul

复星医药(02196.HK) 公布,控股子公司星浩澎博自主研发的1类新药XH-S004用于治疗慢性阻塞性肺疾病(COPD)适应症于近日在中国境内(不包括港澳台地区)启动Ib期临床试验。

公司指,XH-S004为复星医药自主研发的小分子口服二肽基肽酶1(DPP-1)抑制剂,拟用于治疗COPD、非囊性纤维化支气管扩张症等。XH-S004 另一适应症用于治疗非囊性纤维化支气管扩张症在中国境内处于II期临床试验阶段。(ss/u)(港股报价延迟最少十五分钟。沽空资料截至 2025-07-17 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10